The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma
The DNA damage-responsive, 3q26-q29 amplicon-encoded lncRNA PARylator promotes PARP1‑mediated PARylation and SSB repair, thereby limiting DSB accumulation and supporting ESCC cell survival and resistance to DNA-damaging therapies. Targeting PARylator, alone or in combination with DNA-damaging agents, may represent a novel avenue for ESCC treatment.
Authors
- Liu Teng (ORCID: https://orcid.org/0000-0003-3264-2318)
- Tianli Fan
- Man Man Han (ORCID: https://orcid.org/0009-0007-6654-3410)
- Jia Hui Kou
- Teng Fei Qi
- Ting La (ORCID: https://orcid.org/0000-0001-6072-5722)
- M. B. LIU
- Xu Zhang (ORCID: https://orcid.org/0000-0001-8481-0059)
- Hongtao Liu (ORCID: https://orcid.org/0000-0002-6363-7450)
- Wen Li (ORCID: https://orcid.org/0009-0008-2208-4459)
- Yi Yue (ORCID: https://orcid.org/0000-0002-6520-7171)
- Shundong Cang
- Yadong Liu (ORCID: https://orcid.org/0000-0001-7880-0882)
- Jinkun Yang
- Tao Liu
- Xiaoying Liu
- Song Chen
- Yuwei Zhang
- Jing Li
Institutions
- Shanxi Medical University (CN)
- UNSW Sydney (AU)
- Zhengzhou University (CN)
- Children's Cancer Institute Australia (AU)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1186/s40164-025-00739-z
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00